Video – Clinical Trial Results

Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN)

November 18, 2024

Disclosures: TBD

Dr. Katherine R Tuttle and Dr. C. Michael Gibson Discuss: Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial

November 18, 2024

Disclosures: TBD

Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)

November 18, 2024

Disclosures: TBD

Dr. Steven E Nissen and Dr. C. Michael Gibson Discuss: ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks.

November 18, 2024

Disclosures: TBD

Dr. Rajeev K Pathak and Dr. C. Michael Gibson Discuss: Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial

November 18, 2024

Disclosures: TBD

Daniel P Judge and Dr. C. Michael Gibson Discuss: Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

November 18, 2024

Disclosure: Sponsored by BridgeBio

Dr. Kengo Kusano and Dr. C. Michael Gibson Discuss: Cryoballoon Ablation vs. Radiofrequency Ablationno in Patients With Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Noninferiority Clinical Trial

November 18, 2024

Disclosures: TBD

Dr. Mikhail N Kosiborod and Dr. C. Michael Gibson Discuss: Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial

November 18, 2024

Disclosure regarding the REALIZE-K Trial:Dr. Mikhail Kosiborod will become an AstraZeneca BioPharmaceuticals Research and Development Employee as Senior Vice President […]

Dr. Daniel R. Bensimhon and Dr. C. Michael Gibson Discuss: Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)

November 18, 2024

Disclosures: TBD

Dr. Marcely Gimenes Bonatto and Dr. C. Michael Gibson Discuss: Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial

November 18, 2024

Disclosures: TBD